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ABSTRACT 
Multi-drug resistant (MDR) Acinetobacter baumannii is increasingly more 
prevalent in nosocomial infections. Although in vitro susceptibility of A. baumannii 
to minocycline is promising, the in vivo efficacy of minocycline has not been well 
established. Moreover, the shortage of new effective antibiotics against MDR A. 
baumannii has created a need for maximizing the usage of currently available 
antibiotics. Therefore, we proposed to improve the therapeutic outcomes of 
minocycline for infections caused by A. baumannii. Our working hypothesis was 
that therapeutic outcomes could be improved by maximizing minocycline efficacy 
and suppressing the development of resistance in A. baumannii.  
We intended to achieve this proposed goal by: 1) deriving PK parameters for 
minocycline using a murine infection model; 2) determine the exposure-response 
relationship of minocycline; 3) suppressing the development of minocycline 
resistance. Our findings will fill the gaps in knowledge needed to optimize the use 
of minocycline and support its role as a first-line agent in the treatment of A. 
baumannii infections. Moreover, it is anticipated that our strategies for optimizing 
treatment with minocycline may be applicable to other tetracyclines, thereby 
expanding the viable options for MDR A. baumannii infections.  
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CHAPTER 1: INTRODUCTION 
1.1 Background 
Various antibiotics have been developed since penicillin was first used in humans 
in 1940s. However, antimicrobial resistance has made these antibiotics less 
effective.  As a result, there is a shortage of effective antibiotics for the treatment 
of life-threatening bacterial infections (1). According to the Centers for Disease 
Control and Prevention (CDC), at least 2 million people were infected with 
resistant bacteria every year in the United States, and more than 23,000 of them 
died (2). The spread of antimicrobial resistance also increased the economic 
burden of the health care system markedly. In the United States, around $55 
billion were cost by antimicrobial resistance each year (3).  
Acinetobacter is one of the most problematic genus among all the pathogens. 
Infections associated with these bacteria were classified at a “serious concern 
level”, in a report by the Centers for Disease Control and Prevention (CDC). 
About 7% of healthcare-associated infections among the critically ill patients on 
mechanical ventilators were caused by Acinetobacter, and 63% of Acinetobacter 
are multi-drug resistant (MDR) (4). As a typical representative of this genus, 
Acinetobacter baumannii is the most problematic species, because it exhibits an 
outstanding ability to acquire and accumulate multi-drug resistance (5, 6). A. 
baumannii is an opportunistic pathogen, which mostly affects patients with 
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compromised immune function. It is commonly implicated in infections of the 
respiratory tract, bloodstream, urinary tract and skin. In recent years, the 
prevalence of MDR A. baumannii isolates has been increasing (7). Many 
commonly used antimicrobial agents are ineffective, and increased mortality was 
reported in patients infected with MDR A. baumannii (8, 9). In addition, we are 
facing a significant shortage of effective antibiotic agents against infections 
caused by MDR A. baumannii. Thus, improving the efficacy of the currently 
available antibiotics is the need of the hour. 
In 2013, Denys et al. collected the susceptibility data of Gram-negative bacteria 
from the U.S. between 2005 and 2011. In that study (n=883), the susceptibility 
rate of MDR Acinetobacter isolates to minocycline was 72.1 %, whereas most of 
the other drugs examined were found to be resistant (10). The in vitro 
susceptibility results of minocycline for A. baumannii are promising. However, the 
in vivo efficacy was not well established yet, and the currently using dosing 
regimen of minocycline may not be optimal. It is well accepted that antimicrobial 
resistance crisis was mainly caused by misuse of antibiotics, including overuse 
and inappropriate prescribing (1, 11). Improved understanding of the minocycline 
pharmacokinetics and pharmacodynamics is urgently needed. The rationale of 
dosing regimen design could help improving the therapeutic outcomes of 
infections caused by MDR A. baumannii. 
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On the other hand, the understanding of resistance development could help us 
suppress it. There are various known mechanisms that are responsible for 
decreased susceptibility of A. baumannii to antibiotics. The major reported 
resistance mechanisms of A. baumannii against tetracyclines include up-
regulation of efflux pump(s) and ribosomal protection (12). Tetracycline-specific 
efflux pumps are encoded by the tetA and tetB determinants, which could reduce 
intracellular concentration of tetracyclines. Ribosomal protection is regulated by 
tetM, which decreases the affinity of ribosomes to drug molecules (13, 14). In 
addition, multidrug efflux pumps, adeABC and adeIJK, also play an important 
role in tetracyclines resistance (15, 16). This type of efflux pumps could cause 
cross-resistance among multiple classes of antibiotics. Detoxification by enzyme 
and reduced uptake have been reported as tetracycline resistance mechanisms 
in Escherichia coli, other than A. baumannii (14). Among all the mechanisms, the 
most likely one(s) that emerge(s) in vivo during minocycline treatment is unclear.  
In 2011, the study reported by Hornsey, M. and colleagues compared two A. 
baumannii isolates from a patient, by whole genome sequencing. The isolates 
were collected from a patient before and after receiving tigecycline. However, the 
author could not determine whether the change in genome was caused by the 
drug exposure, or the patient initially had a mixed infection (17). In contrast, the 
conditions of animal studies could be well controlled. Therefore, in terms of the 
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clonal relationship with the parent isolate, mutant derived from animal model is 
superior for studying resistance development.  
1.2 Overview 
The overall objective of the proposed research is to improve therapeutic 
outcomes of minocycline against A. baumannii infections. To achieve this 
objective, we plan to study various factors that affect minocycline therapeutic 
outcomes, and which could guide treatment strategies. The project is separated 
into three specific aims as shown below. Briefly, Aim 1 will be focused on the 
pharmacokinetics of minocycline. In Aim 2, we will establish an exposure-
response relationship and strive to improve minocycline in vivo efficacy. Finally, 
Aim 3 is to study resistance development in A. baumannii during therapy. 
1.3 Specific aims 
The limited availability of new antibiotics for MDR A. baumannii makes it 
imperative for us to take a step back to assess the old antibiotics such as 
minocycline. Traditionally designed minocycline dosing regimen may not be 
optimal for MDR A. baumannii. Therefore, we need to optimize dosing strategies 
to improve therapeutic outcomes of minocycline. With the findings of the 
proposed project, minocycline could be re-purposed as an effective treatment 
against A. baumannii infections.  
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There are 3 specific aims in this project: 
Aim 1:  To characterize pharmacokinetics of minocycline. 
Our working hypothesis for this aim is that the PK of minocycline is linear in mice, 
for all the dose levels we evaluate. Therefore, we can use the best-fit PK 
parameters to simulate the corresponding drug exposure for different dosing 
regimens. We will test our hypothesis by performing PK studies with different 
minocycline dose levels.  
Aim 2:  To maximize minocycline in vivo efficacy.  
Our working hypothesis for this aim is that minocycline exposure is correlated to 
the reduction of in vivo bacterial burden. Therefore, efficacy could be improved 
by optimizing the dosing regimen. We will test our hypothesis by establishing the 
exposure-response relationship of minocycline. 
Aim 3:  To study in vivo resistance development in A. baumannii. 
Our working hypothesis for this aim is that development of minocycline 
resistance in A. baumannii can be suppressed by optimizing factors linked to 
resistance development. Therefore, understanding the mechanism(s) of 
resistance development could help improve therapeutic outcomes. We will test 
our hypothesis by studying A. baumannii resistance development in an animal 
infection model. 
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CHAPTER 2: LITERATURE REVIEW 
2.1 Minocycline 
Minocycline, a semi-synthetic derivative of tetracycline, was approved by FDA in 
1970. It has a broad spectrum of activity against Gram-positive and Gram-
negative bacteria. By binding to the 30S ribosomal sub-unit, minocycline can 
inhibit protein synthesis in bacteria. Compared to other tetracyclines, it has 
excellent penetration into tissues and a long elimination half-life (18, 19). Both of 
these are favorable pharmacokinetic properties. Conventionally, minocycline has 
not been used as a first-line agent in Gram-negative bacterial infections. 
However, the shortage of new and effective antibiotics against MDR A. 
baumannii, has motivated us to re-evaluate the utility of minocycline. Despite 
good in vitro results of minocycline against MDR A. baumannii, satisfactory 
clinical response was not consistently seen in patients treated with minocycline 
(20). A higher minocycline daily dose may be necessary for infections caused by 
MDR A. baumannii. Although the typical dosing regimen of minocycline is 200 
mg/day, 400 mg IV q12h with an 800 mg loading dose has been used in humans, 
for acute spinal cord injury (21). Therefore, a higher and safe dose of minocycline 
in human might be feasible. However, the in vivo efficacy of minocycline has not 
been well established and the rationale of the minocycline dosing regimen design 
needs to be further substantiated.  
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Information about bio-distribution of minocycline is limited. In this study, we 
mainly focused on pneumonia, but data regarding pulmonary exposure of 
minocycline in humans is not available. Although a minocycline bio-distribution 
study has been performed in healthy rats by Nagpal, et al, infected animals have 
not been studied yet (22). Inflammation, which is caused by infections, might 
change the permeability of minocycline into lung tissues, as well as the volume of 
distribution. Therefore, we need to characterize pharmacokinetics of minocycline 
in both serum and ELF for the infected animals. 
In addition, serum protein binding is critical for understanding the 
pharmacokinetics and pharmacodynamics of antimicrobial agents. Only the free 
fraction is able to penetrate into extravascular space and exert antimicrobial 
effects. Serum protein binding of minocycline is usually accepted as 76%, which 
was determined by ultrafiltration (23). However, antimicrobial agents may show 
non-linear protein binding due to the saturation of binding sites, and typically the 
percentage of free fraction increases, with increasing total concentration (24, 25). 
Recently, a contrary phenomenon was reported in tigecycline and eravacycline 
(26-28). The percentage of free fraction decreased with increasing total 
concentration. It was suggested that the phenomenon could be due to the 
chelating effect of tetracyclines to divalent metal ions (29). It is possible that other 
tetracyclines would also have the same property (i.e., a class effect). Therefore, 
8 
 
we investigated different factors that might impact the binding of minocycline to 
serum proteins. 
2.2 Hospital-acquired pneumonia 
Hospital-acquired pneumonia (HAP), or nosocomial pneumonia, refers to 
pneumonia occurring at least 48 hours after being admitted in the hospital (30). 
HAP is the second most commonly occurring nosocomial infection (after urinary 
tract infections) (31), and is also the most important cause of death among all the 
hospital-acquired infections (32). In a multistate point-prevalence survey 
published in 2014, HAP accounted for around 22% of all the nosocomial 
infections (33). Usually, HAP is considered to include ventilator-associated 
pneumonia (VAP) and healthcare-associated pneumonia (HCAP). VAP is defined 
as  pneumonia occurring more than 48 to 72 hours after endotracheal intubation, 
while HCAP is defined as pneumonia occurring outside the hospital, but with the 
patients having close contact with the healthcare system (31).  
HAP is mainly caused by Gram-negative bacteria, such as Pseudomonas 
aeruginosa, Escherichia coli, Klebsiella pneumoniae, and Acinetobacter species. 
In addition, methicillin-resistant Staphylococcus aureus (MRSA) is also an 
important pathogen for HAP (33). It was reported that age, male sex, structural 
lung disease and multi-organ system failure are factors which could increase the 
risk of HAP (33). About 1/3 of the HAPs occurred in intensive care unit (ICU), and 
90% of them were VAP (34). The neutropenic murine pneumonia model was 
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used in our project, to mimic the physiological conditions of HAP patients. Details 
of the model have been demonstrated previously (35). Serum tumor necrosis 
factor α (TNF-α) and interleukin 6 (IL-6) were found to be significantly higher in 
infected mice compared with control group, which was similar to the physiological 
conditions of patients with bacterial infections (36). Furthermore, two doses of 
cyclophosphamide administered prior to the experiments could induce 
neutropenia which mimics the condition of immunocompromised patients, who 
are usually vulnerable to HAP. 
2.3 Pharmacokinetic/ Pharmacodynamic (PK/PD) modeling of antibiotics 
In 2013, about 23000 deaths were caused by drug resistant bacteria in the U.S, 
while the number was 25000 in Europe (37). Misuse and sub-optimal dosing of 
antibiotics could be important reasons for treatment failure (38). On the other 
hand, over-dosing drugs will increase the risk of side effects and the cost of 
treatment. Therefore, to optimize dosing regimens of antibiotics, we have to 
understand the relationship between drug exposure and bacterial response.  
For antibiotics, the exposure of the drug in the human body (pharmacokinetics) 
and the response of bacterial pathogen to the drug (pharmacodynamics) could 
be linked by a PK/PD index. There are three commonly used PK/PD indices: the 
peak concentration and minimum inhibitory concentration ratio (Cmax/MIC), 
percentage of dosing interval that drug concentration is above MIC (%T>MIC) 
and area under the concentration-time curve to MIC ratio (AUC/MIC). The PK/PD 
10 
 
index is determined by the killing property of the antibiotics: Cmax/MIC is used 
when antimicrobial activity is concentration-dependent; %T>MIC is used when 
antimicrobial activity is time-dependent; AUC/MIC could be used when 
antimicrobial activity is both concentration and time dependent (38). Usually, the 
best PK/PD index for an antibiotic is determined by a dose fractionation study. 
With a fixed daily dose, the drug could be administered as a single dose or 
smaller doses with different dosing intervals. The most appropriate PK/PD index 
could be identified by comparing the correlation between PK/PD indices and the 
bacterial responses (39). The antimicrobial activities of tetracyclines are usually 
considered as both concentration and time dependent. Therefore, AUC/MIC is 
expected to be the most appropriate PK/PD index for minocycline. 
The relationships between the best PK/PD indices and the bacterial responses 
could be described by an inhibitory sigmoid Emax model (40). With the knowledge 
of exposure-response relationship, the magnitudes of PK/PD indices for the 
required PD targets could be calculated. Clinicians are able to select the optimal 
dosing regimens for the patients and minimize the risk of side effects.  
2.4 Resistance development  
The emergence of resistance is a major problem in antimicrobial therapy. 
Increased mortality, cost and patients’ suffering make it imperative for us to 
understand and suppress the development of resistance. There are three 
commonly accepted mechanisms responsible for bacterial adaptation to the 
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selective conditions. First, the adaptation is caused by altered regulatory 
mechanisms, rather than genetic change; second, the mutation is associated 
with increased copy of gene, which is called gene duplication-amplification (GDA) 
(increased level of enzyme or efflux pumps, etc.); third, the mutation is 
genetically stable, e.g., frameshift, deletion and insertion, etc. The gene 
regulatory response and GDA are usually common and reversible, whereas the 
third one is rare. Therefore, it was considered that GDA is the intermediate step 
of stable genetic mutation (41). Various technologies could be utilized to detect 
genetic mutations, including real-time quantitative PCR and next generation 
genome sequencing, etc.  
During exposure to antimicrobial treatment, there are two ways for bacteria to 
gain genetic resistance: acquired and de novo. In acquired resistance, mobile 
genetic elements are obtained from other bacteria, whereas de novo is 
developed in a step-wise manner through the mechanisms described above (42). 
In this project, we focused on suppressing the de novo pathway in A. baumannii. 
The minimum inhibitory concentration (MIC) of antibiotic may inhibit the visible 
growth of micro-organisms, but may not kill resistant sub-populations. To 
suppress the development of resistance, the mutant prevention concentration 
(MPC) is required. Thus, the MPC is the MIC of the most resistant subpopulation. 
According to the mutant selection window hypothesis, the selection window 
(concentration range between MPC and MIC99, which is drug concentration that 
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inhibits 99% of the subpopulations) is problematic, in terms of selective 
amplification of resistant sub-populations (43). Traditional dosing strategies tend 
to selectively amplify the resistant subpopulations during treatment, since MICs 
of parent isolates are usually used to design dosing regimens. Therefore, 
maintaining the drug concentration above the selection window is the best 
practice for avoiding resistance development (44). In the drug development 
stage, candidates with a narrow selection window are more promising than those 
with simply low MICs. The findings of the current project will help to optimize 
regimens to suppress resistance development in A. baumannii.  
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CHAPTER 3: GENERAL METHODS 
3.1 In vitro microbiology studies 
3.1.1 Quantitative culture 
Quantitative culture is a technique for quantifying bacteria in the sample. Briefly, 
samples were serially diluted with sterile saline (transferring 100 µL sample into 
900 µL saline). An aliquot of sample (200 µL) was dropped onto the Mueller-
Hinton agar (MHA) plate, and spread using the wet sterile cotton swab. The 
plates were incubated at 37°C overnight. A valid colony number (n) should be 
between 20 and 200. The bacterial burden was calculated as Log10(n*5) + 
dilution factor, and the unit of bacterial burden was log10 CFU/mL. 
3.1.2 Minimum inhibitory concentrations 
The minimum inhibitory concentrations (MICs) were defined as the lowest 
concentrations of chemicals that inhibit the visible growth of micro-organisms. 
The values indicate susceptibility of micro-organisms to the chemicals. MIC could 
be determined in liquid growth medium (broth) or on the surface of solid growth 
medium (agar). In the current project, both broth dilution method and ETEST 
approach were used to determine MICs of various antibiotics against the A. 
baumannii isolates. 
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3.1.2.1 Broth dilution method 
The protocol of broth dilution method followed the guidance of the Clinical and 
Laboratory Standards Institute (CLSI) (45). A concentration range which includes 
the anticipated MIC value was chosen for the antibiotic. The antibiotic was 
serially diluted by cation-adjusted Mueller-Hinton broth (Ca-MHB) into twice as 
much of the desired concentrations. An aliquot of 250 µL antibiotics was mixed 
with equal volume of bacterial suspension (106 CFU/mL of bacteria in Ca-MHB). 
Negative control was filled with 500 µL of Ca-MHB, while positive control was a 
mixture of 250 µL Ca-MHB and an equal volume of the bacterial suspension. 
Tubes were incubated at 37°C for 16 - 20 hours, and vortexed again. The MIC 
values were read at 24h of incubation. MIC of the antibiotic was the lowest 
concentration that the corresponding tube was clear. 
3.1.2.2 ETEST 
In ETEST method, the antibiotics were preloaded on a plastic strip, and the MICs 
were determined by the bacterial inhibition zone. Briefly, the concentration of 
bacterial cell suspension in Ca-MHB was adjusted to 0.15-0.25 absorbance at 
590nm wavelength. The suspension was spread on the MHA plates by a sterile 
cotton swab within 20 minutes. The excess moisture could be absorbed by the 
agar completely, after approximately 15-20min. ETEST strips were applied to the 
surface of inoculated agar with forceps. The air pockets under the strip could be 
removed by pressing gently on the strip without moving it. Agar plates were 
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incubated at 37 °C for 16-20 hours, and the lowest concentration of the inhibition 
zone was the corresponding MIC.  
3.2 Neutropenic murine pneumonia model 
A neutropenic murine pneumonia model was used in this project. The 
experimental setup was as previously described (35, 46). Female Swiss Webster 
mice weighing between 20 and 25 g (Harlan, Indianapolis, IN) were rendered 
neutropenic by two doses of intraperitoneal cyclophosphamide, prior to the 
experiment (150 mg/kg in day -4 and 100 mg/kg in day -1). Neutropenia could 
minimize the impacts of innate immune function and therefore reduce the inter-
subject variability of the animals.  
The animals were anesthetized by one dose of intraperitoneal 1.25% Avertin (2, 
2, 2-Tribromoethanol) (approximate 0.3 mL). Avertin was prepared by mixing 125 
mg 2,2,2-tribromoethanol and 0.25 mL tert-amyl alcohol (Sigma-Aldrich) with 10 
mL injection water. An overnight culture of bacteria was inoculated in fresh broth, 
and grown to log phase. Then the bacterial suspension was concentrated to the 
desired burden, on the basis of absorbance at 630 nm. The anesthetized mice 
were inoculated with approximately 107 - 108 colony forming unit (CFU) of A. 
baumannii under laryngoscopic guidance. The protocol was approved by 
Institutional Animal Care and Use Committee of the University of Houston. The 
immune response in mice after infection has been studied previously in our lab. 
Serum tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6) were found to be 
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significantly higher in the infected mice, compared with the control group (36). 
The results were consistent with the pathophysiology of patients with severe 
pneumonia (47).  
3.3 LC-MS/MS assay method development 
The liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to 
determine drug concentrations in serum and epithelial lining fluid (ELF) samples. 
The LC-MS/MS system consists of a Waters AcquityTM UPLC with Waters BEH 
C18 column (1.7µm 2.1x50mm) and API5500 Qtrap triple quadrupole mass 
spectrometer (Applied Biosystem/MDS SCIEX, Foster City, CA, USA) equipped 
with Turbo-Ion-Spray TM source. The mobile phase A and B were 0.1% formic 
acid in distilled water and acetonitrile, respectively. 
3.3.1 Chromatographic and mass spectrometric conditions 
In the Ultra Performance Liquid Chromatography (UPLC) system, analytes were 
separated by gradient elution, which was: 0-0.5min: 98% A; 0.5-0.7min: 98-84% 
A; 0.7-1.2 min: 84-76% A; 1.2-1.7min:  76-70% A; 1.7-2.1min: 70-50% A; 2.1-2.5 
min: 50-5% A; 2.5-3.0min: 5% A; 3.0-3.2min: 5-98% A; 3.2-5min: 98% A.  The 
flow rate was set at 0.35 ml/min, and the temperature of the column was 45°C. 
The temperature of the sample chamber was maintained at 15°C. For the mass 
spectrum, the curtain gas, ionspray voltage, temperature, ion source gas 1 and 
gas 2 were 20, 5000 V, 500°C, 35 and 40, respectively. 
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3.3.2 Assay method validation 
For all the tested compounds, the methods have been validated at three different 
concentration levels (L: low, M: medium, H: high). LLOQ (Lowest Limit of 
Quantification) was defined as the concentration of drug peak with 10 times 
height of baseline, while HLOQ (Highest Limit of Quantification) was the highest 
concentration tested in the validation. For different compounds, the sample 
preparation procedures will be described in Chapter 4. 
3.3.2.1 Standards and quality controls 
Stock solutions of antibiotics (8192 mg/L) were prepared by dissolving drugs in 
water separately, and stored at -80°C. The stock solutions were thawed for 
preparing standard solutions prior to experiments, and serially diluted with 
distilled water or 0.5% (V/V) methyl-sulfoxide (DMSO). Quality control samples 
(QC) were made by diluting stock solution into different concentrations with 
serum or ELF, and stocked in -80℃ .  
3.3.2.2 Accuracy and precision 
Accuracy and intra-day precision were determined by analyzing 6 QC samples 
for each concentration level within 1 day. The inter-day precision was assessed 
by repeating the same experiment twice on different days. Therefore, there were 
6 samples for intra-day precision and 18 samples for inter-day precision, at each 
concentration level. Meanwhile, a standard curve generated by serially diluted 
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standards was prepared every day. According to the standard curve, 
concentration of each sample was determined. Accuracy was calculated as the 
average concentrations of QC divided by the nominal values, while precision was 
calculated as the standard deviation of the QC concentrations divided by their 
mean values (coefficient of variation). 
3.3.2.3 Recovery and matrix effects 
The recovery and matrix effects of 3 concentration levels were evaluated (L, M, 
H). Three different sets of samples were analyzed for determining recovery and 
matrix effects, and all the samples were triplicated. Set A was prepared in the 
same method as QC. Set B was the neat solution of analytes (dissolved in 10% 
acetonitrile for levofloxacin or in 50% methanol for minocycline and doxycycline). 
Set C was prepared by reconstituting blank matrix residual with set B. The peak 
area of analytes was used for calculation. Recovery was the ratio between set A 
and set C values, and matrix effects was the ratio between set C and set B 
values. 
3.3.2.4 Data analysis 
The results were analyzed in Multiquant 2.0.2. The 1/X2 weighted linear 
regression was used for the standard curves. The acceptable accuracy range of 
each concentration level is 85-115%, and the precision must be within 15%. The 
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extent of recovery should be close to 100%, while matrix effects should be close 
to 0. Both of them have to be consistent across all concentration levels. 
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CHAPTER 4: PHARMACOKINETICS OF MINOCYCLINE 
To translate our findings clinically, we need to explore the pharmacokinetics of 
minocycline in the neutropenic murine pneumonia model. The results of our 
studies could be correlated to patients in terms of the relevant drug exposure 
(AUC, concentration, etc.). In this chapter, we developed and validated a LC-
MS/MS assay method for minocycline in mouse serum and ELF. The assay 
methods of doxycycline and levofloxacin in mouse serum were also validated. 
The serum protein binding of minocycline was investigated by an in vitro 
microdialysis system. Finally, a modified 2-compartment PK model was used to 
fit the minocycline serum and ELF concentration data. 
4.1 Materials and methods 
4.1.1 Materials 
Liquid chromatography-mass spectrometry (LC-MS)-grade water, methanol and 
acetonitrile were purchased from EMD Millipore Corporation (Billerica, MA).  
Methyl-sulfoxide (DMSO) was obtained from EM SCIENCE (Gibbstown, NJ). LC-
MS-grade formic acid, minocycline hydrochloride, doxycycline hyclat, HEPES, 
dipotassium phosphate (K2HPO4) and monopotassium phosphate (KH2PO4) 
were purchased from Sigma-Aldrich (St. Louis, MO). Mouse and human sera 
were obtained from Equitech-Bio, Inc (Kerrville, TX). Mueller Hinton II Broth 
(cation-adjusted) was manufactured by BD Diagnostic Systems Europe. The 
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urea assay kit was from BioAssay Systems (Hayward, CA). CMA 12 Elite 
Microdialysis Probe was a product of CMA Microdialysis (Reference number 
8010434; Stockholm, Sweden). The semi permeable membrane (20,000 Da cut-
off) was made of polyarylethersulfone (PAES).  
4.1.2 LC-MS/MS assay  
4.1.2.1 Minocycline and doxycycline 
The chromatographic conditions have been described in section 3.3.1. The 
multiple-reaction monitoring (MRM) scan type in positive mode was used for 
mass spectrum. The transitions were m/z 458.3 to 441.2 and m/z 445.2 to 154.2 
for minocycline and doxycycline, respectively. The declustering potential (DP), 
collision energy (CE) and collision cell exit potential (CXP) of minocycline were 
55, 25 and 20; while the values of doxycycline were 50, 23 and 20, respectively. 
The sample preparation procedures were similar for these 2 drugs, and they 
were used as internal standard for each other. For standards, 10 µL of blank 
serum or ELF was mixed with 10 µL of standard solutions (0.5% DMSO, V/V) 
and 30 µL of internal standard solution (10 µg/ml in water). For serum or ELF 
samples, 10 µL of sample was mixed with 10 µL of 0.5% DMSO (V/V) and 30 µL 
of internal standard solution (10 µg/ml in water). Each tube was added 170 µL of 
acetonitrile (containing 0.03% formic acid, V/V).  After vortexing for 30 seconds, 
the samples were centrifuged for 15 minutes at 18000x g. An aliquot of 40 µL 
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supernatants were transferred to a new tube, and evaporated under a stream of 
ambient air. After being reconstituted with 1 mL of 50% methanol, 5 µL of the 
samples were injected into the UPLC system. The assay methods were validated 
as described in section 3.3.2. 
4.1.2.2 Levofloxacin 
The chromatographic conditions for levofloxacin were similar to that for 
minocycline and doxycycline. The multiple-reaction monitoring (MRM) scan type 
in positive mode was used. The transitions were m/z 362.1 to 318.1 and m/z 
332.1 to 268.3 for levofloxacin and ciprofloxacin (internal standard), respectively. 
The DP, CE and CXP of levofloxacin were 65, 25 and 20; while the values of 
ciprofloxacin were 40, 30 and 11, respectively. 
For standards, 10 µL of blank serum was mixed with 10 µL of standard solutions 
and 20 µL of internal standard (ciprofloxacin in 1% ammonium hydroxide, 8 
mg/L). For samples, 10 µL of serum samples were mixed with 10 µL of distilled 
water and 20 µL of internal standard (ciprofloxacin in 1% ammonium hydroxide, 8 
mg/L). Each tube was added 170 µL of acetonitrile. After vortexing for 15 
seconds, the samples were centrifuged for 15 minutes at 18000X g. An aliquot of 
20 µL supernatants were transferred to a new tube, and mixed with 220 µL of 
distilled water. The samples were ready for analysis, and the injection volume 
was 3 µL.  The assay methods were validated as described in section 3.3.2. 
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4.1.3 Serum protein binding 
4.1.3.1 Microdialysis 
Serum protein bindings of minocycline, doxycycline and levofloxacin were 
determined by in vitro microdialysis as described previously (26, 48). Briefly, a 
probe was inserted into a reservoir tube (containing serum spiked with an 
antimicrobial agent, incubated at 37°C). The perfusion medium was perfused 
through probe at the flow rate of 1.5 µL/min. The system was equilibrated for 30 
minutes, and then dialysates were collected between 30-40 and 40-50 minutes. 
Concurrent samples from reservoir tube were also collected at 30, 40 and 50 
minutes. Recovery of the microdialysis system was determined similarly and 
separately for each experiment; the reservoir tube was filled with a perfusion 
medium instead of serum. To minimize the non-specific binding of drugs to the 
tubing and membrane, the system was pre-conditioned by the same setup for 50 
minutes. The experiments were performed at least twice on different days and 
the free fraction was calculated by the average of the results. Schematic 
microdialysis setup was shown in Figure 1, and the serum protein bindings were 
calculated by the equations below. 
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Figure 1: Schematic microdialysis setup for protein binding determination 
 
 
 
Recovery =  
2 ×Cd,recovery(T1,T2)
Cr,recovery(T1)+Cr,recovery(T2)
  
Free fraction =  
2 ×Cd(T1,T2)
Cr(T1)+Cr(T2)
 ×
1
Recovery
   
Where Cd (T1, T2): Dialysate concentration collected between time 1 and time 2; 
                          Cr: Concentration of sample taken from reservoir tube 
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4.1.3.2 Time-kill 
Time-kill study was used as functional verification of minocycline serum protein 
binding. Studies performed previously in our lab suggested that the growth profile 
of A. baumannii in serum was similar as that in half-strength cation-adjusted 
Mueller-Hinton broth (0.5X Ca-MHB) (49). Briefly, the A. baumannii isolate was 
inoculated into 5mL sterile mouse serum or 0.5X Ca-MHB, and the inoculum was 
approximately 5 × 105 CFU/mL. The bacteria were incubated in a shaker water 
bath at 37°C. Serial samples were collected at different time points over 6h.  
Samples were centrifuged at 10000X g and 4°C for 15min, the supernatants 
were subsequently replaced by same volume of sterile saline. Finally, bacteria 
were quantified by quantitative culture as described in section 3.1.1.  
4.1.4 Minocycline in vivo exposure 
The single-dose pharmacokinetics of minocycline in mouse serum and ELF were 
characterized. The neutropenic murine pneumonia model was described in 
section 3.2. Minocycline was administered intraperitoneally in 67 animals 2h after 
infection. Serum or bronchoalveolar lavage (BAL) samples were collected serially 
over time (n≥3 for each time point). Blood samples were collected by cardiac 
puncture. BAL samples were recovered through the trachea after 1 mL of saline 
was injected into the lungs. Minocycline concentrations were determined by the 
LC-MS/MS method as detailed in 4.1.2.1. The minocycline concentrations in ELF 
were calculated by correcting minocycline concentrations in BAL with urea 
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concentrations as described previously (50).  The serum and ELF concentration-
time profiles were co-modelled by a modified two compartmental model in 
ADAPT 5 (51) (as shown in Figure 2 ). Three regimens were initially evaluated: 
25 mg/kg, 50 mg/kg and 100 mg/kg. Based on the preliminary results, a 
humanized regimen mimicking the human serum concentration-time profile of 
minocycline (when a clinical dose of 200 mg is given intravenously to humans) 
was validated. The area under the curve (AUC) of the serum and ELF 
concentration-time profiles were derived by integrating the best-fit instantaneous 
concentrations with respect to time. Pulmonary penetration ratio of minocycline 
was estimated by the AUC ratio of ELF to serum.  
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Figure 2: Structure of the pharmacokinetic model  
 
 Differential equations: 
dAserum / dt = ka × Adepot + kpc × AELF / P – (kcp + ke) × Aserum 
dAELF / dt = kcp × Aserum – kpc × AELF / P 
dAdepot / dt = – ka × Adepot 
Adepot: Amount of minocycline in depot created by IP injection 
AELF and Aserum: Amount of minocycline in ELF and serum; 
kcp, kpc: Inter-compartmental transfer rate constants; 
ka, ke: Absorption and elimination rate constants; 
P: Minocycline penetration ratio between lung ELF and serum. 
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4.2 Results 
4.2.1 LC-MS/MS assay 
4.2.1.1 Minocycline and doxycycline 
The retention times of minocycline and doxycycline were 2.5 and 3.1 minutes, 
respectively. The chromatogram was shown in Figure 3. The linear range of 
minocycline and doxycycline were 0.0625-128 mg/L and 0.125-64 mg/L, 
respectively (as shown in Figure 4). The results of LC-MS/MS assay validation 
were shown in Table 1.  
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Figure 3: Chromatogram of minocycline and doxycycline 
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Figure 4: Calibration curve of minocycline and doxycycline 
A. Minocycline 
 
B. Doxycycline 
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Table 1: Validation of minocycline and doxycycline LC-MS/MS assay 
 
A. Minocycline 
Matrix 
 
L (0.5mg/L) M (8mg/L) H (128mg/L) 
Mouse 
serum 
Intra-day (n=6) 
Accuracy 101.2% 101.1% 99.6% 
Precision 2.5% 2.2% 2.3% 
Inter-day (n=18) 
Accuracy 100.5% 101.6% 96.5% 
Precision 3.4% 3.4% 3.6% 
Recovery (n=3) 102.4% 98.8% 101.4% 
Matrix effects (n=3) 89.1% 100.2% 103.1% 
Mouse  
ELF 
Intra-day accuracy (n=6) 102.4% 89.7% 96.9% 
Matrix effects (n=3) 97.5% 89.0% 88.1% 
 
B. Doxycycline 
Matrix 
 
L (0.25mg/L) M (4mg/L) H (64mg/L) 
Mouse 
serum 
Intra-day (n=6) 
Accuracy 103.5% 94.8% 116.5% 
Precision 9.0% 7.0% 6.7% 
Recovery (n=3) 132.0% 95.1% 104.5% 
Matrix effects (n=3) 97.8% 104.2% 96.9% 
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4.2.1.2 Levofloxacin 
The retention times of levofloxacin and ciprofloxacin were both 2.3 minutes. The 
chromatogram was shown in Figure 5. The linear range of levofloxacin is 0.25-
64mg/L (as shown in Figure 6). The results of LC-MS/MS assay validation were 
shown in Table 2.  
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Figure 5: Chromatogram of levofloxacin and ciprofloxacin 
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Figure 6: Calibration curve of levofloxacin 
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Table 2: Validation of levofloxacin LC-MS/MS assay 
 
Matrix 
 
L (2mg/L) M (16mg/L) H (64mg/L) 
Human 
 serum 
Intra-day (n=6) 
Accuracy 100.5% 98.7% 94.9% 
Precision 5.7% 4.5% 6.7% 
Inter-day precision (n=18) 10.0% 11.3% 8.6% 
Recovery (n=3) 105.3% 97.0% 112.5% 
Matrix effects (n=3) 85.2% 91.2% 81.2% 
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4.2.2 Serum protein binding 
4.2.2.1 Microdialysis 
The protein binding of minocycline in mouse serum was studied at 4 
concentrations (0.5, 5, 15 and 50 mg/L), and 4 perfusion media [saline (sterile 
0.9% (W/V) sodium chloride solution), 0.1M HEPES buffer (pH=7.4, adjusted by 
sodium hydroxide), 0.1M and 1M PBS (pH=7.4)] were used. Both sterile and un-
processed mouse sera were used in the study, and no difference was observed. 
Free fractions of minocycline were shown in Figure 7. For all the perfusion media 
examined, the values decreased with the increase of total minocycline 
concentrations. Of note, the binding values could also vary among various 
perfusion media using the same total minocycline concentration. Compared to 
the buffer groups, the saline group had considerably lower free fraction values.  
Similar experiments were performed using human serum and a consistent trend 
was observed to that in mouse serum (Figure 8). Finally, protein bindings of 
doxycycline and levofloxacin in mouse serum were also determined at 3 
concentrations (0.5, 5 and 50 mg/L), using saline as the perfusion medium. The 
free fractions of doxycycline and levofloxacin in mouse serum were shown in 
Figure 9. Doxycycline had a similar trend of concentration-dependent protein 
binding, but the free fractions were slightly higher than that of minocycline. On 
the contrary, the protein binding values for levofloxacin were similar, and 
consistent with previously reported values (24 to 38%) (52). 
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Figure 7: Free fraction of minocycline in mouse serum 
 
 
Note: Data shown as mean ± SD. Different media were used for perfusion. 
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Figure 8: Free fraction of minocycline in mouse and human sera 
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Figure 9: Free fraction of minocycline, doxycycline and levofloxacin in 
mouse serum 
 
 
Note: Data shown as mean ± SD. Saline was used as the perfusion medium. 
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4.2.2.2 Time-kill 
The growth profile of AB BAA 747 in mouse serum was comparable to that in half 
strength Ca-MHB (as shown in Figure 10). The profile of 2 mg/L minocycline in 
serum was comparable to that of 0.05 mg/L minocycline in 0.5X Ca-MHB. 
However, when minocycline concentration in 0.5X Ca-MHB increased to 0.1 
mg/L, the corresponding profile in serum required 50 mg/L minocycline (as 
shown in Figure 11).  
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Figure 10: Time-kill results of placebo in serum or 0.5X Ca-MHB 
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Figure 11: Time-kill results of minocycline in serum or 0.5X Ca-MHB 
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4.2.3 Minocycline pharmacokinetic study 
The initial estimation of serum AUC0-24h and the best-fit Cmax suggested that the 
pharmacokinetics of 25 mg/kg and 50 mg/kg doses were within the linear range. 
Also, the daily dose of 50 mg/kg was found to be comparable to the human 
equivalent AUC reported in a previous study (35). Therefore, the total daily dose 
was split into 5 doses to mimic a humanized regimen. Briefly, 18 mg/kg of 
minocycline was given at 0 h to achieve the serum Cmax similar to that in humans, 
and 4 supplemental doses (11 mg/kg, 9 mg/kg, 8 mg/kg and 4 mg/kg given at 4 
h, 9 h, 14 h and 22 h) were given to maintain the serum concentrations around 
the target pharmacokinetic profile reported in humans (18).  
The data from these 3 dosing regimens were co-modeled, and PK parameters 
were shown in Table 3. The best-fit minocycline concentration-time profiles of 
different dosing regimens were shown in Figure 12. The profiles of minocycline in 
both serum (r2 = 0.977) and ELF (r2 = 0.952) were captured satisfactorily (as 
shown in Figure 13). The elimination half-life in serum was 2.6 h. The serum 
AUC0-24h were 34 mg*h/L, 68 mg*h/L and 63 mg*h/L for 25 mg/kg, 50 mg/kg and 
humanized regimen, respectively; while the ELF AUC0-24h were 94 mg*h/L, 189 
mg*h/L and 175 mg*h/L. The pulmonary penetration ratio of minocycline was 2.8.  
Compared to 50 mg/kg, the AUC0-24h of the 100 mg/kg dose observed was more 
than 3 times higher. Therefore, the concentration-time profiles of 100 mg/kg were 
analyzed separately (as shown in Figure 12), and PK parameters were shown in 
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Table 3. The r2 were 0.971 and 0.867 for serum and ELF concentration-time 
profiles (as shown in Figure 13). The elimination half-life was prolonged (3.9 h), 
suggesting saturable clearance for the 100 mg/kg dose. The AUC0-24h were 227 
mg*h/L and 564 mg*h/L for serum and ELF, respectively. The pulmonary 
penetration ratio was 2.5.  
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Table 3: Best-fit PK parameters 
 
PK parameters 
Group 1  
(25, 50 mg/kg and 
 humanized regimen) 
Group 2  
(100 mg/kg) 
Ke (1/h) 0.27 0.18 
Vc (L/kg) 2.7 2.4 
Ka (1/h) 2.3 4.6 
Pulmonary penetration ratio 2.8 2.5 
t1/2 (h) 2.6 3.9 
CL (L/h/kg) 0.7 0.4 
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Figure 12: Minocycline serum and ELF concentration-time profiles 
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     Note: The observed data were shown as mean ± SD. 
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Figure 13: Correlation between observed and best-fit PK data 
 
A. 25 mg/kg, 50 mg/kg and humanized regimen 
 
 
 
 
 
 
B. 100 mg/kg 
 
 
 
 
 
Note: The dashed line is the line of identity (i.e., y=x). 
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CHAPTER 5: MAXIMIZE MINOCYCLINE IN VIVO EFFICACY 
To maximize minocycline in vivo efficacy, we need to explore the drug exposure-
response relationship. Due to the complexity of serum protein binding, ELF 
exposure was used instead of systemic free drug exposure in the PK/PD 
modeling. Then the PK/PD magnitudes for different PD targets could be 
determined by the model. 
5.1 Materials and methods 
5.1.1 Materials 
The Ultra Clean microbial DNA isolation kit was from Mo Bio laboratories, Inc. 
(Carlsbad, CA); DNA Acinetobacter strain typing kit was a product of Diversilab 
(Marcy I’Etoile, France), and Taq DNA polymerase was purchased from Bioline 
USA Inc (Randolph, MA).  The urea assay kit was from BioAssay Systems 
(Hayward, CA).  
5.1.2 Bacterial isolates 
5.1.2.1 In vitro susceptibility 
Five A. baumannii isolates (1 laboratory wild-type isolate and 4 clinical isolates) 
with a wide range of minocycline MICs were used. Susceptibilities to minocycline, 
doxycycline, amikacin and imipenem were determined by the broth dilution 
method as recommended by CLSI (as described in section 3.1.2.1). 
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Pseudomonas aeruginosa strain ATCC 27853 (American Type Culture 
Collection, Manassas, VA) was used as a control strain. In addition, the MICs of 
minocycline for 4 isolates were determined in the in the presence of phenylanine-
arginine β-naphthylamide (PAβN) (100 mg/L), an efflux pump inhibitor (53). In 
order to exclude the inhibitory effect of PAβN, the bacterial burden of each 
positive control was determined by QC as described in section 3.1.1. 
5.1.2.2 Clonal relatedness 
The clonal relatedness of the A. baumannii isolates was assessed by repetitive-
element–based polymerase chain reaction (rep-PCR) (54, 55). Briefly, genomic 
DNA was isolated using Ultra Clean microbial DNA isolation kit, and used as the 
template for the Acinetobacter strain typing kit. The PCR reaction was performed 
on 2720 Thermal Cycler (Applied Biosystems, CA). The AmpliTaq DNA 
Polymerase was used, and the total reaction volume was 25 µL. Parameters of 
Thermal Cycler was listed in Table 4. The DNA fragments of rep-PCR products 
were separated by the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa 
Clara, CA), and compared by the DiversiLab software using the Pearson 
correlation coefficient (Bacterial Barcodes, Inc., Athens, GA). 
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Table 4: Parameters of AB 2720 Thermal Cycler 
 
Steps Temperature (°C) Time (seconds) 
Initial Denaturation 94 120 
Denaturation 94 30 
Annealing 50 30 
Extension 70 90 
Final Extension 70 180 
Hold 4 - 
Cycles 35 
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5.1.2.3 Resistance mechanisms 
Colony quantitative PCR (qPCR) was carried out to determine the presence of 
the tetA, tetB, tetM, and tet39 genes in A. baumannii strains. Colonies of 
overnight-streaked strains on LB agar plates were chosen, resuspended, heated, 
and used as PCR templates. The qPCR was run using Sybr green Select master 
mix (ABI) in an ABI 7000 sequence detection system. The threshold cycle (CT) 
values were normalized with the housekeeping gene recA of the same strain. 
The difference (ΔCT) was used as a logarithmic power (base = 2) to calculate the 
relative signal of the gene. The transcription levels of the known efflux genes, 
adeB, adeJ, and adeG, were determined by reverse transcription (RT)-qPCR. 
Cells were grown in cation-adjusted Mueller-Hinton broth (Ca-MHB) and 
centrifuged, and total RNA was isolated (Ambion RiboPure Bacteria RNA 
isolation kit [ABI]). The RT reaction was performed using the TaqMan reverse 
transcriptase reagent kit (ABI) with a mixture of primers. The results (CTs) were 
normalized with the housekeeping gene rpoB. 
5.1.3 Minocycline in vivo PD study 
The mice were inoculated with approximately 107 CFU of A. baumannii isolate by 
the methods described in section 3.2. Infected animals were treated with different 
dosing regimens of minocycline about 2 h after infection. For reference, there 
was a no treatment control group for each bacterial isolate. There were 80 
animals given 23 dosing regimen - bacterium combinations in total (n≥3 for each 
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regimen). For reference, there was a placebo (i.e., no treatment) control group 
for each bacterial isolate. The bacterial burdens in lung tissues were determined 
at 0h (baseline) and 24h after first dose of minocycline as described elsewhere 
(35, 56). Briefly, after the animals were sacrificed by CO2 asphyxiation, the lung 
tissues were harvested and homogenized in sterile saline. Pulmonary bacterial 
burdens were determined by quantitative culture (as shown in section 3.1.1), and 
normalized by the weights of lung tissues.  
5.1.4 Data analysis 
The relationships between minocycline PK/PD indices (unbound drug exposures 
in ELF) and bacterial burden in lung tissues at 24 h were described by an 
inhibitory sigmoid Emax model (as shown in Figure 14) (40). The coefficient of 
determination was used to discriminate the PK/PD index most closely correlated 
to bactericidal activity. In addition, the best-fit parameters were also used to 
derive the required PK/PD magnitudes for maintaining stasis or achieving 1 log 
reduction of bacterial tissue burden at 24h. 
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Figure 14: Inhibitory sigmoid Emax model 
 
 
Inhibitory sigmoid Emax model: E= E0 – Emax × X
H / (IX50
H + XH) 
E: PD response at 24h 
E0: the top of the curve 
Emax: the maximum effect 
X: the value of PK/PD index (ELF) 
IX50: the required value of X to achieve 50% of the Emax 
H: the Hill slope of the curve 
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5.2 Results 
5.2.1 Susceptibility and clonality assessment 
The tetracycline resistance mechanisms and susceptibilities of the A. baumannii 
isolates to various antibiotics were shown in Table 5. No effects were attributed 
to the PAβN concentration used (data not shown). In the presence of PAβN, the 
MIC of AB7416 was not as low as those of the other strains. It is unclear if this is 
due to the presence of tetB or another, alternative mechanisms(s). Cross-
resistance was observed between minocycline and doxycycline. The isolates 
were found to belong to 3 clonally diverse groups (as shown in Figure 15 below). 
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Table 5: Susceptibilities of A. baumannii isolates 
 
Note: Bold fonts depict resistant phenotype as defined by the Clinical and 
Laboratory Standards Institute (CLSI) 
 
 
 
 
 
 
Isolate Source 
Tetracyline 
resistance 
mechanism(s) 
MIC (mg/L)  
Minocycline 
/Minocycline+PAβN 
Doxycycline Imipenem Amikacin 
AB BAA 
747 
Laboratory Wild-type 0.25/0.125 0.25 0.25 2 
AB 7283 Clinical 
Moderate 
overexpression 
of adeB 
0.5/0.125 0.5 128 128 
AB 1261 Clinical 
Moderate 
overexpression 
of adeB 
1/0.125 0.5 128 128 
AB 1129 Clinical 
adeABC and 
adeIJK 
overexpressed 
4/- 4 8 32 
AB 7416 Clinical 
tetB, moderate 
overexpression 
of adeB 
16/2 128 16 > 512 
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Figure 15: Dendrogram of A. baumannii clonality. 
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5.2.2 Minocycline in vivo PD study 
The baseline bacterial burdens in lung tissues ranged from 7.75 to 8.18 log 
CFU/g. In the absence of treatment, the tissue burdens increased to 8.60 to 9.65 
log CFU/g in 24h. All treatment groups infected with the minocycline-resistant 
isolate (AB7416) showed similar results as the no treatment control group, while 
the other susceptible / intermediate isolates were suppressed to various extents. 
Different dosing regimens with the daily dose of 50 mg/kg (i.e., 50 mg/kg single 
dose, 25 mg/kg every 12 h and humanized regimen) were given to mice infected 
with AB 7283, AB 1261 and AB 7416. For each isolate, there were no significant 
differences in bacterial burden at 24 h among these 3 dosing regimens. 
Therefore, ELF AUC/MIC should be the most appropriate PK/PD index for 
minocycline. 
5.2.3 PK/PD correlation 
According to the best-fit PK parameters, the PK/PD indices for ELF profiles of 
different dosing regimens against various A. baumannii isolates were calculated, 
and listed in Table 6. The relationships between minocycline PK/PD indices in 
ELF and bacterial tissue burden at 24h were shown in Figure 16. The strongest 
relationship was observed when the tissue burdens were correlated with AUCELF 
0-24h/MIC (r
2 = 0.81). Using the best-fit parameters, the required AUCELF 0-24h/MIC 
for maintaining stasis was 140, and the required AUCELF 0-24h/MIC for achieving 1 
log reduction was 410. 
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Table 6: PK/PD indices for ELF profiles of different dosing regimens 
against various A. baumannii isolates 
AUC/MIC 
 
AB BAA 747 AB 7283 AB 1261 AB 1129 AB 7416 
Placebo 0 0 0 0 0 
25mg/kg 377 189 94 24 6 
25mg/kg x 2 743 371 186 46 12 
50mg/kg 755 377 189 47 12 
Humanized 701 351 175 44 11 
50mg/kg x 2 1478 739 369 92 23 
100mg/kg 2258 1129 564 141 35 
 
%T>MIC 
 
AB BAA 747 AB 7283 AB 1261 AB 1129 AB 7416 
Placebo 0 0 0 0 0 
25mg/kg 74 63 52 30 7 
25mg/kg x 2 100 100 100 61 14 
50mg/kg 85 74 63 41 19 
Humanized 100 100 100 80 0 
50mg/kg x 2 100 100 100 83 39 
100mg/kg 100 100 100 81 46 
 
Cmax/MIC 
 
AB BAA 747 AB 7283 AB 1261 AB 1129 AB 7416 
Placebo 0 0 0 0 0 
25mg/kg 76.1 38.1 19.0 4.8 1.2 
25mg/kg x 2 79.5 39.8 19.9 5.0 1.2 
50mg/kg 152.2 76.1 38.1 9.5 2.4 
Humanized 55.4 27.7 13.8 3.5 0.9 
50mg/kg x 2 159.1 79.5 39.8 9.9 2.5 
100mg/kg 333.6 166.8 83.4 20.8 5.2 
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Figure 16: Correlation of PK/PD indices in ELF and tissue burden at 24h 
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Each data point represents an observation from a single animal. In view of the 
logarithmic scale used, AUC/MIC values were input as 1 and Cmax/MIC values 
were input as 0.1 for placebo controls. 
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CHAPTER 6: RESISTANCE DEVELOPMENT 
To explore mechanisms of minocycline resistance development during therapy, 
resistant mutants of laboratory wild type strain AB BAA 747 were isolated from 
mouse lung tissue samples. In future, whole genome sequencing (WGS) will be 
used to identify mutant genes. In this chapter, the mutants were characterized to 
ensure clonal relatedness and stable susceptibility. Additional studies, such as 
cross resistance and growth rate, could provide more information for future 
studies about the resistance development mechanism. 
6.1 Materials and methods 
6.1.1 Resistant mutant preparation 
The same neutropenic murine pneumonia model as described in section 3.2, was 
used for resistant mutant preparation. The mice were infected with approximately 
107 CFU of AB BAA 747 (laboratory wild type isolate). A repeated dose of 
minocycline (25mg/kg) was administered everyday by intraperitoneal injection. 
The bacterial burdens in lung tissues were determined at 0h (baseline), 24h and 
48h after the first dose of minocycline. Resistant mutants were isolated by plating 
lung tissue sample on Mueller-Hinton agar plates, which contain 2 times MIC of 
minocycline (0.5 mg/L). The plates were incubated at 37°C, and mutants of 48h 
samples were collected.  
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6.1.2 Mutational frequency 
Mutational frequencies were calculated as the number of resistant mutants 
divided by the total bacterial burden. The in vitro baseline mutational frequency of 
AB BAA 747 was determined by inoculating approximately 109 CFU of bacteria 
on the minocycline-supplemented agar plates (2× MIC). Plates were incubated 
at 37°C, and the number of resistant mutants was determined after 48h. Mutants 
were collected for later susceptibility test. The inoculum was confirmed by 
quantitative culture as described in section 3.1.1. The sample was prepared in 
triplicate, and the experiment was repeated three times on different days. Finally, 
the average of mutational frequency values was reported. Similarly, the 
mutational frequencies of AB BAA 747 in mouse lung tissue samples were also 
determined. 
6.1.3 Characterization of the mutants 
6.1.3.1 Susceptibility and stability of mutants 
The MICs of minocycline for AB BAA 747 resistant mutants were determined by 
ETEST as described in section 3.1.2.2. The parent isolate AB BAA 747 was used 
as a control. To verify the stability of the mutation, mutants were sub-cultured in 
drug-free Ca-MHB 5 times. The MICs of minocycline were determined again. In 
addition, the MICs of levofloxacin for all the mutants were also determined by 
ETEST. 
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6.1.3.2 Time growth 
Time growth studies of AB BAA 747 and the mutants were performed in 216Dx 
UTI System (BacterioScan, MO). Briefly, each isolate was inoculated into Ca-
MHB, and incubated at 37 °C water bath, until achieving the log phase. Bacteria 
were diluted to approximately 5 × 105 CFU/mL, and 2 mL of each was transferred 
into the cuvette. The run time of the time growth study was 90 minutes, and the 
sampling interval was 5 minutes. Reads of bacterial burden were calibrated for 
AB BAA 747. A first order kinetics equation was used to fit the collected data in 
ADAPT 5. The differential equation was as shown below. The confidence 
intervals of kg were used to compare AB BAA 747 and the mutants. 
                                dN(t)/dt = N(t)*kg 
N(t): Size of bacterial population at time t; 
                                kg: growth rate constant. 
 
6.1.3.3 Repetitive Sequence-based polymerase chain reaction 
The clonal relatedness of the parent isolates and mutants was assessed by 
repetitive-element–based polymerase chain reaction (rep-PCR) as described in 
section 5.1.2.2. The procedure was modified due to the availability of reagents. 
Briefly, the PCR reaction was performed on ProFlex PCR system (Life 
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Technologies, Inc.). Primer was from the DiversiLab strain typing kit for 
Acinetobacter (BioMerieux, France). The GoTaq DNA Polymerase was used, 
and the total reaction volume was 25 µL. Parameters of PCR system were the 
same as that in Table 4. The DNA fragments of rep-PCR products were 
separated by the Agilent 4200 TapeStation system (Agilent Technologies, Santa 
Clara, CA). The high sensitivity D5000 tape was used, and AB 7416 was used as 
negative control. 
6.1.3.4 Pulsed-field gel electrophoresis 
Pulsed-field gel electrophoresis (PFGE) was used to further confirm the clonal 
relatedness of all the A. baumannii isolates. A previously published PFGE 
method for A. baumannii was modified in our study (57). Briefly, 3 mL of the 
overnight culture was centrifuged (3200×g, 4°C) for 15 minutes. The supernatant 
was discarded, and the pellet was re-suspended by 1mL cell suspension buffer 
(CSB: 100mM Tris-HCL, 10mM EDTA). The same volume of 1.6% low melting 
point agarose was mixed with the bacterial cell suspension, and the mixture was 
poured into mold to make insert plug. The plugs were incubated in 0.5mL cell 
lysis solution 1(CLS-1: 50mM Tris-HCL, 50mM EDTA, 2.5mg/mL lysozyme, 
150mg/L proteinase K) at 37°C for 5h, and then moved into 0.5mL CLS-2 
(0.5mM EDTA, 1% sarcosyl, 50mg/L proteinase K) at 55°C overnight. Plugs were 
washed with 5mL sterile ultra-pure water at 55°C for 15 minutes (3 times), and 
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then washed similarly by Tris-EDTA (TE). The plugs could be stored in TE buffer 
at 4°C for up to 2 years. 
ApaI endo-nuclease enzyme (New England Biolabs, MA) was used for restrictive 
digestion of genomic DNA (30U/sample). Plugs were incubated at 25°C 
overnight, washed with pure water, and then incubated in TE at 37°C for 1h. The 
PFGE gel consisted of 1.6% I.D.NA agarose (Lonza, Switzerland). DNA 
fragments were separated by a CHEF-DR III system (Bio-Rad Laboratories, 
Belgium) at 14°C, with 6 V/cm2 for 24h. The initial and final switch times were 2s 
and 28s, respectively. The gel was stained with 5µg/mL ethidium bromide for 
20min, and then de-stained in pure water for 30min. The results were visualized 
under UV lights. 
6.2 Results 
6.2.1 Mutational frequency 
The in vitro baseline mutational frequency of AB BAA 747 was 2.3×10-7. Ten 
mutants were randomly collected, and all of them showed elevated MIC of 
minocycline (≥3 times). After being passed 5 times in drug-free Ca-MHB, nine of 
them still showed stable susceptibility to minocycline (data is not shown here).  
For animal studies, increased average mutational frequency was observed, when 
mice were administered 25mg/kg/day minocycline. The mutational frequency 
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over time was shown in Figure 17. Nine resistant mutants were collected from 3 
mice at 48h.  
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Figure 17: Mutational frequency of AB BAA 747 collected from lung tissue 
samples 
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6.2.2 Characterization of mutants 
6.2.2.1 MIC and stability of mutation 
The MICs of minocycline for AB BAA 747 and its mutants were shown in Table 7. 
Compared to the parent isolates, seven out of nine isolates were observed 
elevated MIC (≥3 times). After being sub-cultured in drug free Ca-MHB for 5 
times, all the mutants showed stable elevated MIC. The susceptibilities of 
mutants to levofloxacin were also shown in the table, and two of the mutants 
showed cross-resistance between minocycline and levofloxacin. 
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Table 7: Susceptibility and stability of the mutants  
 
Strain 
Minocycline MIC 
(mg/L) 
Minocycline MIC 
after 5 days (mg/L) 
Levofloxacin MIC 
(mg/L) 
AB BAA 747 0.25 0.5 0.25 
Mutant 1 1.5 2 0.19 
Mutant 2 1.5 2 0.19 
Mutant 3 1.5 1.5 0.19 
Mutant 4 1.5 1.5 0.75 
Mutant 5 1.5 2 0.19 
Mutant 6 1.5 1.5 0.19 
Mutant 7 0.25 0.38 - 
Mutant 8 2 2 0.75 
Mutant 9 0.25 0.38 - 
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6.2.2.2 Time growth 
Seven mutants with elevated MICs were included in time growth study. Three out 
of seven isolates grew significantly slower than the parent isolate. The results 
were shown in Figure 18, and the growth rate constants were shown in Table 8.  
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Figure 18: Time growth results of AB BAA 747 and the mutants 
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Table 8: Growth rate constants of AB BAA 747 and the mutants 
 
 
kg (1/h) 
95% confidence interval of kg 
r2 
Low High 
AB BAA 747 1.854 1.743 1.965 0.993 
Mutant 1 1.86 1.746 1.974 0.993 
Mutant 2 2.029 1.937 2.121 0.996 
Mutant 3 1.636 1.493 1.779 0.985 
Mutant 4 1.842 1.683 2.001 0.985 
Mutant 5 1.576 1.47 1.682 0.991 
Mutant 6 1.618 1.503 1.733 0.990 
Mutant 8 1.214 1.112 1.315 0.983 
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6.2.2.3 Repetitive Sequence-based polymerase chain reaction 
Mutant 8 was excluded from this step due to the impurity of the isolate. The 
results of rep-PCR products in TapeStation were shown in Figure 19. All the 
mutants showed a pattern similar to that of AB BAA 747, and AB7416 showed 
different patterns. 
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Figure 19: Results of rep-PCR products in TapeStation 
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6.2.2.4 Pulsed-field gel electrophoresis 
The Photo of PFGE gel was shown in Figure 20. The tested isolates showed 
similar patterns of bands. Compared to AB BAA 747, only 1 additional band was 
observed for mutant 3 and 5.  
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Figure 20: Results of pulsed-field gel electrophoresis 
 
 
78 
 
CHAPTER 7: CONCLUSIONS  
7.1 Serum protein binding 
Tigecycline and eravacycline were previously reported to have atypical non-linear 
serum protein binding; the free fraction decreased with increasing total 
concentration. In this study, we extended the investigations to other tetracyclines 
and examined if this could be a generalized class effect. 
Although serum protein binding is known to play an important role in PK and PD 
of drugs, no standard method has been established yet. There are various 
methods available for determining serum protein binding, such as equilibrium 
dialysis, ultrafiltration, microdialysis, ultracentrifugation, fluorescence 
spectroscopy as well as chromatography and capillary electrophoresis (58). In 
addition, in vitro time-kill study could provide functional validation of the serum 
protein binding, although it is not as accurate as the analytical chemistry 
approaches (49). Usually, equilibrium dialysis is considered as the “reference 
method”， because it is more precise than other approaches (59, 60). However, 
it is time-consuming and labor-intensive. In contrast, microdialysis shares similar 
mechanism with equilibrium dialysis, but requires less time. The system has 
been well established, and been described in many papers (26, 61-63).  
In the current study, within a clinically achievable concentration range, 
minocycline and doxycycline were found to have the same trend of protein 
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binding as tigecycline. The atypical non-linear protein binding appears consistent 
across several tetracyclines. Serum protein binding of minocycline is usually 
accepted as 76% (determined by ultrafiltration) (23), and is similar to our results 
using PBS with a low minocycline concentration. If the atypical non-linear protein 
binding is confirmed, the use of tetracyclines for the treatment of bacteremia 
should be re-evaluated. This is especially relevant for pathogens with low to 
intermediate-level resistance, as higher doses may not yield better therapeutic 
outcomes. The exact mechanisms of the atypical non-linear protein binding is not 
clear, Singh RS et al. suggested that it could be caused by chelating effect of 
tetracyclines to divalent metal ions (29). The addition of 
ethylenediaminetetraacetic acid (EDTA) resulted higher unbound fraction, and 
the atypical profile disappeared. Moreover, our results also suggested that 
different perfusion media used might also have an impact on the microdialysis 
results. Therefore, specific conditions of the microdialysis experiments require 
further optimization / standardization. Correlating the results from in vitro systems 
to in vivo microdialysis should also be considered (64). 
In addition, time-kill studies with different minocycline concentrations in mouse 
serum or 0.5X Ca-MHB were used as functional validation of minocycline serum 
protein binding. Although, calculated protein binding values were higher than that 
derived by microdialysis, the observed trend of nonlinear serum protein binding 
was same as that in microdialysis studies. When minocycline concentration in 
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0.5X Ca-MHB increased from 0.05 to 0.1 mg/L, the comparable minocycline 
concentration in serum increased from 2 to 50 mg/L. 
In summary, serum protein binding of minocycline is atypically concentration-
dependent. In addition, the microdialysis results could vary considerably when 
different perfusion media are used. To understand the mechanism(s) and clinical 
implications of serum protein binding to minocycline, additional studies are 
warranted.  
7.2 Pharmacokinetics of minocycline 
Because of high lipophilicity, about 95%-100% of orally administered minocycline 
could be absorbed, and it has the highest penetration into organs among all the 
tetracyclines (65). In the current study, minocycline exposure in ELF was higher 
than systemic total drug exposure (2.5-2.8×). In the treatment of pneumonia, this 
property will lead to drug accumulation in the site of infection. Although the 
distribution of minocycline in humans ELF has not been reported, the ratio of 
minocycline concentrations between bronchial secretions and blood was studied 
before. However, the results were not consistent from one study to another, and 
the values ranged from 0.3 to 2.2 (23, 65-67). To optimize dosing regimen of 
minocycline in humans, a better understanding of the bio-distribution is required. 
Therefore, more data of minocycline bio-distribution in humans is desired. 
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The PK parameters of minocycline in animals and humans have been studied 
previously. In horses, the elimination half-life was 7.7 ± 1.9 h (mean ± SD) after a 
2.2 mg/kg single IV injection (68). A prolonged half-life (11.5 ± 3.2 h, mean ± SD) 
at steady state was observed when the dose was increased to 4 mg/kg q12h 
(69). The observation of non-linear pharmacokinetics reported with high doses 
was consistent with our findings from the current study (100 mg/kg in mice), and 
might be due to saturation of drug metabolism (70). Minocycline has variety of 
metabolites in humans. Two mono-N-demethylated derivatives and 9-
hydroxyminocycline were reported to be the major metabolites (70). With 
API5500 Qtrap triple quadrupole mass spectrometer, the same metabolites have 
been identified in mouse serum PK sample too (data not shown in here). The 
elimination half-life in humans ranged from 12 h to 18 h, and the AUC0-∞ of serum 
concentration-time profile were 70-86 mg*h/L after 200 mg was given 
intravenously (18). Only 8-20% of the dose was recovered from human urine (65, 
71). Therefore, little increase of elimination half-life was observed in renal 
impaired patients (72, 73). Up to 800 mg of minocycline daily has been given 
intravenously in a clinical trial for acute spinal cord injury (21), however there is 
little known to date about the dose linearity of minocycline in humans.  A 
prospective study examining the safety, tolerability, and pharmacokinetics of 
minocycline (single and multiple ascending doses) in heathy adults has been 
planned (ClinicalTrials.gov identifier: NCT02802631). In clinically achievable 
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dose, if the non-linear clearance of minocycline was also observed in humans, 
better therapeutic outcomes are expected due to the extra drug exposure. 
In conclusion, the pharmacokinetics of minocycline in mice serum and ELF were 
characterized. These findings could facilitate subsequent PK/PD study of 
minocycline for infections caused by A. baumannii. 
7.3 Exposure-response relationship of minocycline 
The shortage of new effective antibiotics against MDR A. baumannii prompted us 
to maximize the effectiveness of the currently available drugs, such as 
minocycline. With a good understanding of the drug exposures and bacterial 
susceptibilities likely to be encountered, a PK/PD model could facilitate the 
optimal use of minocycline. In vitro susceptibility results of minocycline are 
promising. Denys et al. reported the susceptibility data of Gram-negative bacteria 
from the U.S. between 2005 and 2011. In that study (n=883), the susceptibility 
rate of MDR Acinetobacter isolates to minocycline was 72.1 %, whereas most of 
other drugs examined were found to be resistant (10). Therefore, we want 
maximize minocycline in vivo efficacy by exploring the exposure-response 
relationship. 
Free drug exposures in serum are commonly used in PK/PD studies. In the 
current study, we found that minocycline concentrations in ELF were higher than 
those observed in the serum. Subsequently, the PK/PD analysis was performed 
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with unbound minocycline concentrations in ELF (i.e., the site of infection), as 
they were deemed to be more relevant to therapeutic outcomes of pneumonia. 
Furthermore, serum protein binding of the tetracyclines may not be as straight 
forward as one might anticipate. Tigecycline was previously shown to exhibit 
atypical serum protein binding; the fraction of binding was higher with increasing 
total drug concentration in serum (26). The serum protein binding of minocycline 
was found to be dependent on the experimental conditions. Microdialysis data 
suggested that protein bindings of minocycline in human and mouse sera were 
comparable at different concentrations (results shown in Figure 8).  Since the 
ELF exposure of minocycline achieved in humans after a clinical dose is not 
available, the total drug concentration-time profiles in the serum was mimicked 
and we assumed pulmonary penetration ratios of minocycline in humans and 
mice were similar.  
The first step of PK/PD modeling was to determine the most appropriate PK/PD 
index for minocycline. As we discussed in section 2.3, there are three commonly 
used PK/PD indices: Cmax/MIC, %T>MIC and AUC/MIC. Dose fractionation study 
could help determining the best PK/PD index for antibiotics. Briefly, the same 
daily dose could be designed into different regimens. The most appropriate 
PK/PD index is determined by comparing the PD response: 1) If the PD response 
of different regimens are similar, we should choose AUC/MIC; 2) If the PD 
response of the single dosing regimen is the best, Cmax/MIC is the best PK/PD 
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index; 3) If the PD response of the most frequent regimen is the best, the PD/PD 
index should be %T>MIC. In the current study, we used 3 different bacterial 
isolates, and the regimens with the same daily dose (50 mg/kg single dose, 25 
mg/kg every 12 h and humanized regimen) showed similar in vivo efficacy (data 
not shown here). Since these dosing regimens have similar AUC0-24h but different 
Cmax and %T>MIC, AUCELF 0-24h/MIC was expected be the PK/PD index best 
correlating to the bacterial burden. The subsequent study was tested with 5 A. 
baumannii isolates. Using a wide range of minocycline exposure and bacterial 
susceptibility (23 dosing regimen – bacterium combinations in total), our initial 
finding was substantiated by the results of the full PK/PD analysis (as shown in 
Figure 16). 
The PK/PD model described the relationship between minocycline exposure and 
bactericidal activity quantitatively. Maximum efficacy observed was 
approximately 1.5 log reduction of bacterial burdens from baseline. The required 
AUCELF 0-24h/MIC values for maintaining stasis or achieving 1 log reduction of 
bacterial tissue burdens were also estimated. AUCELF 0-24h of humanized regimen 
(a clinical dose of 200 mg is given intravenously to humans) was 175 mg*h/L. 
With a MIC of 0.25 mg/L, the corresponding AUCELF 0-24h/MIC (700) is expected 
to achieve more than 1-log kill. However, the therapeutic outcomes will vary 
when the MICs are different. Using these estimates, minocycline dosing 
regimens could be optimized when the susceptibility of an A. baumannii isolate is 
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known. Furthermore, it is also important to avoid selective amplification of the 
resistant subpopulation(s) during treatment. In the future, additional studies are 
warranted to evaluate resistance development during therapy, and correlating 
minocycline exposures to therapeutic outcomes of patients with infections 
caused by A. baumannii. 
In conclusion, we have identified threshold target exposures for achieving 
different PD responses in A. baumannii infections, and the information could be 
used to optimize minocycline dosing regimens. 
7.4 In vivo resistance development 
Increased mutational frequencies were observed for AB BAA 747 at 24h and 48h 
after the first dose, when mice were administered 25mg/kg/day. Six of the 
mutants isolated from mouse lung tissue samples had elevated MICs of 
minocycline. Cross resistance was observed for two of the mutants (mutant 4 
and 8) between minocycline and levofloxacin, which suggests the existence of 
multi-drug efflux pumps over expression. To further confirm this hypothesis, 
quantitative PCR could be used to compare expression of adeABC and adeIJK 
(15, 16).  
The clonal relatedness of the parent isolate and the mutants were determined by 
rep-PCR and PFGE. Both the results suggested that the selected mutants 
belonged to the same clonal family of AB BAA 747. The rep-PCR products of AB 
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isolates were previously separated by Agilent 2100 Bioanalyzer system, as 
described in 5.1.2.2. Due to the availability of reagents for Bioanalyzer, the 
Agilent 4200 TapeStation system was used. In rep-PCR study, the observed 
band patterns were the same for all the isolates. In PFGE study, only two 
mutants (mutant 3 and 5) were found to have one additional band, and the rest of 
the mutants had the same band pattern as AB BAA 747. According to the 
previously published criteria, AB BAA 747 and the mutants could be considered 
as “closely related” (74). There are several reasons that could cause changes in 
PFGE pattern:  1) The additional DNA fragments might be contributed by plasmid 
(75); 2) Genomic DNA may gain extra restriction sites, therefore some of the 
larger DNA fragments were broken into smaller fragments (76); 3) Similarly, loss 
of curtain genes that contain restriction sites could also change the PFGE 
patterns (77). Compared to AB BAA 747, only mutant 5 showed significantly 
slower growth rate. Mutant 3 also had decreased growth rate, but the difference 
was not significant. Both of them did not show cross resistance to levofloxacin, 
which suggested that the mutation did not involve over expression of multi-drug 
efflux pumps. 
Better understanding of the functions that controlled by the mutant genes could 
help us optimize the regimen of minocycline, and then suppress resistance 
development in A. baumannii. In future, these isolates will be analyzed by whole 
genome sequencing to identify the mutant genes. Among all the isolates, mutant 
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5 should be the first choice, because it had the most different phenotypes from 
the parent isolate. We expect mutant 5 will give us more information about the 
mechanisms of resistance development.   
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CHAPTER 8: FUTURE DIRECTIONS 
The minocycline serum protein binding was determined in the current study. 
Because of its complexity, we only confirmed the atypical non-linear serum 
protein binding of minocycline. It was found that different perfusion media applied 
in the microdialysis system could affect the results, and none of the results 
matched that of time-kill studies. To confirm the serum protein binding of 
minocycline, further studies are needed. Microdialysis could be used in vivo as 
well as the in vitro system (64). The previously described rat portal vein and 
jugular vein intubation model might be used for our future studies (78, 79). The 
simultaneous dialysate samples could be taken with the blood samples, and 
quantified by LC-MS/MS. This approach could eliminate the differences between 
in vitro and in vivo systems, and provide more accurate results.  
The exposure-response relationship of minocycline for A. baumannii has been 
demonstrated in our studies, and the resistant mutants of AB BAA 747 have 
been isolated from mouse lung tissue sample. The stability of susceptibility and 
clonal relatedness for the six mutants have been confirmed. In future, these 
mutants could be used for studying the mechanisms of minocycline resistance 
development. The whole genome sequencing (WGS) technology will be applied 
to identify the mutant genes. Briefly, genomic DNA of selected resistant mutants 
and AB BAA 747 will be extracted. Genomic DNA of all strains will be fragmented 
and sequenced as paired-end reads on the HiSeq sequencing system (Illumina, 
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San Diego, CA, USA). Contigs will be determined by analyzing the raw genome 
sequence, and the reads will be aligned to the reference genome using Seqman 
by DNAStar. The SNPs (single nucleotide polymorphisms) and gene deletions 
will be identified by comparing the sequences. 
As discussed in section 1.1, the elevated MIC of minocycline for A. baumannii 
might be caused by up-regulation of efflux pumps (tetA, tetB, adeABC and 
adeIJK, etc.) or ribosomal protection (tetM). The collected isolates may contain 
the mutant genes above, or other unknown mechanisms. The WGS results will 
reveal the genomic alternations of the mutants. If the functions of mutant gene(s) 
have been reported previously, it could be identified using BLAST (basic local 
alignment search tool) algorithm. Therefore, the gene(s) could be linked to 
reported resistance mechanism(s), and the gene(s) could be further confirmed by 
quantitative PCR. If the function of the identified gene(s) is unknown, editing the 
target gene (e.g. knocking in or out the gene) in mutants could help us 
understand the mechanisms. It is also possible that the development of 
resistance cannot be identified by mutational changes in DNA, but rather in the 
transcriptional changes of the derivatives (80). Comparative transcriptome 
analysis (by RNA sequencing) may be necessary.  
The information obtained could guide modification of treatment strategy (dose 
adjustment or combination therapy). Although the typical regimen of minocycline 
in adults is 200 mg/day, up to 800 mg/day has been given intravenously in a 
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clinical trial for acute spinal cord injury (21). Therefore, a higher dose of 
minocycline might be used to improve therapeutic outcomes. Current treatment 
strategies for MDR A. baumannii include a combination of tigecycline, 
minocycline, carbapenems, polymyxins, and daptomycin (81-84). However, the 
rationales of selecting certain antibiotics for combination therapy were not well 
established. According to our previous study, compared to monotherapy, 
combination of minocycline and polymyxin B could improve therapeutic outcomes 
of pneumonia caused by A. baumannii (35). In that study, we hypothesized that 
polymyxin B could disrupt the cell membrane and the proper functioning of the 
efflux pumps, thereby enhancing the activity of minocycline. Increased 
intracellular minocycline concentrations were also observed when A. baumannii 
was exposed to polymyxin B. This study is an example of designing combination 
therapy based on the resistance mechanism. In future, with more information 
provided by WGS, we may discover more relevant mechanisms, and more 
treatment strategies could be considered for improving therapeutic outcomes of 
infections caused by A. baumannii. 
The antibiotics from the same family share similar chemical, structural and 
antimicrobial mechanisms. Cross-resistance is usually observed for antibiotics 
from the same family. Therefore, we expect that the knowledge of minocycline 
could also be extended to other tetracyclines, and we will have more choices 
when treating infections caused by A. baumannii. 
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CHAPTER 9: CONTRIBUTION TO SCIENCE 
In this project, we characterized the pharmacokinetics of minocycline in 
neutropenic murine pneumonia model, and then explored the in vivo exposure-
response relationship of minocycline for infections caused by A. baumannii. One 
resistant mutant was selected for future resistance development mechanisms 
study. 
The LC-MS/MS method developed for various antibiotics in our study was rapid, 
robust and sensitive. The run time for each sample was 5 minutes, including 
enough equilibration time between injections.  The standard curve showed very 
good linearity within the clinical relevant serum concentration range, and only 10 
µL of serum was needed for each sample. This method could be applied to 
clinical PK samples too, and it will considerably reduce the required amount of 
blood samples from patients. In addition, more antibiotics from various classes 
could be analyzed by the same method, and some of them have been validated 
(85). 
The atypical nonlinear plasma protein binding of tigecycline and eravacycline has 
been reported before. Our studies confirmed that minocycline and doxycycline 
had the same trend of protein binding, which suggested that it could be a class 
effect of tetracyclines. In that case, we need to be cautious when using 
tetracyclines for septicemia caused by intermediate susceptible bacteria, as 
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increased doses may not result higher systemic free drug exposure. Meanwhile, 
we found that different perfusion media in the microdialysis system could give us 
different results. This property may not be important to the drugs with low serum 
protein binding. However, it is critical to drugs like minocycline, because the free 
portion could be around 6 folds different when using different perfusion media 
(typical Cmax of minocycline in humans is 4 mg/L after 200mg IV bolus injection). 
It will remarkably increase the difficulty of projecting effective dosing regimens for 
humans. Therefore, standardized method is needed in future to make results 
from different protein binding studies comparable.  
Because of promising in vitro efficacy, minocycline became a choice for patients 
infected with MDR A. baumannii. However, the in vivo efficacy has not been well 
established. The PK/PD model developed in our studies delineated the in vivo 
exposure-response relationship of minocycline for infection caused by A. 
baumannii. Usually, systemic drug exposure is used in PK/PD modeling for 
antibiotics. However, we used a modified PK model to describe drug exposure in 
the site of infection instead, which was more relevant to the treatment of 
pneumonia. This approach also circumvented the complexity of minocycline 
serum protein binding. We expected that the findings could be translated 
clinically, and then be used to optimize dosing regimen of minocycline. In future, 
this PK/PD model could provide rationale of minocycline dosing regimen design 
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for MDR A. baumannii. Using antibiotics correctly will considerably improve the 
success rate of treatment, and then reduce mortality of infections. 
Although the minocycline resistance mechanisms in A. baumannii have been well 
studied, the information about how the resistance developed in vivo is 
unavailable. The resistant mutant of A. baumannii collected in our study could be 
a good tool for studying in vivo resistance development. It was derived from the 
wild type isolate (AB BAA 747), which exposed to minocycline in a neutropenic 
murine pneumonia model. The clonal relatedness between the mutants and AB 
BAA 747 has been confirmed. In future, the mutant gene(s) could be identified by 
whole genome sequencing. In addition to the currently known resistance 
mechanisms, this approach could also help discovering the potential unknown 
mechanism(s). Such information is expected to provide solutions for suppressing 
minocycline resistance development in A. baumannii.  
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